| (EUR) | Dec 2025 | Y/Y change |
|---|---|---|
| Revenue | 19.13M | -62.78% |
| Operating expense | — | — |
| Net income | -13.24M | -183.56% |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, NP5.F returned +38.0% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -51.6% |
| 1 year | +38.0% |
| 5 years | +574.0% |
| 10 years | -43.9% |
| All-time high | €43.67 (Jul 2007) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in NP5.F would be worth today ›No. Newron Pharmaceuticals S.p.A. has not paid a dividend in the past 12 months.
Newron Pharmaceuticals S.p.A. is part of the Healthcare sector.
Newron Pharmaceuticals S.p.A. has a market cap of 268.39M EUR, based on the latest quote.